StreetInsider.com News Articles

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Mon, 27 Apr 2026 08:00:00 -0400

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.
To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment

Apollomics Announces Settlement of Cayman Litigation

Wed, 19 Nov 2025 17:38:00 -0400

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company’s merger with Maxpro

Apollomics Announces Settlement of Cayman Litigation

Wed, 19 Nov 2025 17:38:00 -0400

Apollomics Announces Settlement of Cayman Litigation

Wed, 19 Nov 2025 17:38:00 -0400

Apollomics Announces Settlement of Cayman Litigation

Wed, 19 Nov 2025 17:38:00 -0400

Apollomics Announces Settlement of Cayman Litigation

Wed, 19 Nov 2025 17:38:00 -0400

Apollomics Announces Settlement of Cayman Litigation

Wed, 19 Nov 2025 17:38:00 -0400

Apollomics remains listed on NASDAQ after compliance determination

Wed, 15 Oct 2025 14:37:06 -0400

Apollomics Inc. (NASDAQ: APLM) will continue trading on The Nasdaq Stock Market after receiving notification that it meets the exchange's continued listing requirements, the company announced.

The California-based biopharmaceutical company had previously received a delisting notification from Nasdaq's Listing Qualifications Staff and filed an appeal requesting a hearing before a Nasdaq Hearings Panel. On October 14, 2025, Nasdaq informed Apollomics that the Staff determined the company is in compliance with continued listing requirements.

As a result, Nasdaq cancelled the scheduled appeal hearing and Apollomics' securities will remain listed on the exchange.

Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies. The

Apollomics remains listed on NASDAQ after compliance determination

Wed, 15 Oct 2025 14:37:06 -0400

Apollomics Inc. (NASDAQ: APLM) will continue trading on The Nasdaq Stock Market after receiving notification that it meets the exchange's continued listing requirements, the company announced.

As a result, Nasdaq cancelled the scheduled appeal hearing and Apollomics' securities will remain listed on the exchange.

Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies. The

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Wed, 15 Oct 2025 14:36:00 -0400

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff’s delisting determination. The Company today announced that it had received a letter from Nasdaq on October 14, 2025, notifying Apollomics

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Wed, 15 Oct 2025 14:36:00 -0400

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Wed, 15 Oct 2025 14:36:00 -0400

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Wed, 15 Oct 2025 14:36:00 -0400

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Wed, 15 Oct 2025 14:36:00 -0400

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Wed, 15 Oct 2025 14:36:00 -0400

NASDAQ resumes trading in Apollomics shares and warrants

Tue, 14 Oct 2025 16:06:01 -0400

NASDAQ announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ: APLM) and warrants (NASDAQ: APLMW) on October 15, 2025, at 9:00 a.m. and 9:05 a.m. Eastern Time, respectively.

Trading in the company's Class A ordinary shares and warrants was halted on September 17, 2025, at 2:37:17 p.m. Eastern Time. The halt lasted approximately four weeks before NASDAQ authorized the resumption of trading.

The announcement was made by The Nasdaq Stock Market (NASDAQ: NDAQ) on October 14, 2025, according to a press release statement.